Skip to main content
. 2019 Aug 21;39(11):1343–1357. doi: 10.1177/0333102419864132

Figure 3.

Figure 3.

Frequently reported treatment-emergent adverse events (a) by percentage of patients and (b) by percentage of attacks (safety population).

AE: adverse event; MedDRA: Medical Dictionary for Regulatory Activities.

Note: Reported by ≥ 2% of patients in either treatment group. An AE that started or worsened within 48 hours after the last dose (either the first or the second dose) of lasmiditan was considered treatment-emergent. AEs were coded using MedDRA Version 21.0.